ArticleFrontiers in immunology2017
Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook.
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Recent Advances in Camel Immunology.Frontiers in immunology · 2020Pooled it
- Generation and evaluation of multimers of anti C-reactive protein Nb and alkaline phosphatase based on three self-assembly peptides.Experimental and therapeutic medicine · 2026Article
- Processing-Induced Modifications of Camel Milk Immunoglobulins and Lactoferrin: Implications for Immunocompromised Pediatric Populations and Therapeutic Applications.Foods (Basel, Switzerland) · 2026Review
- Camelid-Derived Nanobodies Targeting Human Epidermal Growth Factor Receptor: Screening, Expression, and Functional Validation.Antibodies (Basel, Switzerland) · 2026Article
- Discovery of Anti-SARS-CoV-2 XBB.1.5 and JN.1 Variant-Specific Monoclonal Single-Domain Antibodies from a Synthetic Library.Antibodies (Basel, Switzerland) · 2026Article
- Electrochemical Biosensors for Cancer Diagnosis and Prognosis Using Protein Biomarkers: Current Trends, Advances, and Clinical Translation Potential.Sensors (Basel, Switzerland) · 2026Review
- An integrated cell and medium engineering approach for production of a nanobody fusion in Saccharomyces cerevisiae.Applied microbiology and biotechnology · 2026Article
- Identification and characterization of novel antimicrobial peptides fromFrontiers in immunology · 2026Article
- Revisiting the Ofatumumab Epitope on CD20 through Integrative Molecular Dynamics and Flow Cytometry Analyses.Computational and structural biotechnology journal · 2026Article
- VNpj viruses · 2025Article
- A multivalent nanobody-drug conjugate to prevent and treat influenza virus infections.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Multifunctional Nanobody Fusion Proteins in Immunoassays: Diverse Strategies for Enhanced Analytical Performance.Trends in analytical chemistry : TRAC · 2025Article
- Review
- Immunoelectron microscopy: a comprehensive guide from sample preparation to high-resolution imaging.Discover nano · 2025Review
- Allergenicity, Genotoxicity and Subchronic Toxicity Assessment of IgG Binding Protein LT Produced From Aspergillus oryzae.Journal of applied toxicology : JAT · 2025Article
- PET and SPECT Imaging of Macrophages in the Tumor Stroma: An Update.Journal of clinical medicine · 2025Review
- Optimization of a sarbecovirus llama nanobody-antigen binding interface via a combined computational and phage display protein engineering approach.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- A phage-displayed nanobody-based competitive immunoassay for the detection of African swine fever virus antibodies.Virology journal · 2025Article
- Orthogonal Site-Specific Dual Bioconjugation of Aryl and Alkyl Thiols.Journal of the American Chemical Society · 2025Article
- Nanobodies: From Discovery to AI-Driven Design.Biology · 2025Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tremendous effort has been expended over the past two and a half decades to understand many aspects of camelid heavy chain antibodies, from their biology, evolution, and immunogenetics to their potential applications in various fields of research and medicine. In this article, I present a historical perspective on the development of camelid single-domain antibodies (sdAbs or V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.